Immunotherapy for Renal Cell Carcinoma
Immunotherapy for Renal Cell Carcinoma
复制标题
DOI：
10.1016/j.hoc.2011.04.010
复制
发表时间：
2011-08-01
影响因子：
2.4
通讯作者：
McDermott, David F.
中科院分区：
文献类型：
--
作者：
Rosenblatt, Jacalyn;McDermott, David F.
尽管几种细胞因子在肾癌(RCC)中显示出抗肿瘤活性，但最一致的结果是白细胞介素2(IL-2)和干扰素(干扰素)。最近对肿瘤免疫反应如何调节的见解有望使患者获得持久的免疫治疗反应，也许没有与传统方法相关的重大毒性。这篇综述描述了在患者选择、联合治疗和研究药物方面的改进如何扩大和更好地确定免疫治疗在转移性肾细胞癌中的作用。
Although several cytokines have shown antitumor activity in renal cell carcinoma (RCC), the most consistent results have been reported with interleukin-2 (IL-2) and interferon (IFN). Recent insights into how the immune response to a tumor is regulated hold the promise of allowing patients to obtain a durable response to immunotherapy, perhaps without the significant toxicity associated with conventional approaches. This review describes how improvements in patient selection, combination therapy, and investigational agents might expand and better define the role of immunotherapy in metastatic RCC.